CJC-1295 (No DAC) Research Peptide: Background, Mechanism & Research

CJC-1295 is often studied alongside growth hormone-releasing peptides (GHRPs). The form without a Drug Affinity Complex (DAC) — sometimes called Mod GRF 1-29 — is of particular interest for how it influences growth hormone (GH) secretion. Its properties matter to researchers working on the growth hormone axis.

Research Background

Growth hormone regulates a range of physiological processes, including growth, metabolism, and tissue repair. Its release from the pituitary is controlled by growth hormone-releasing hormone (GHRH), which stimulates GH release, and somatostatin, which inhibits it. CJC-1295 is a synthetic GHRH analog built to mimic the natural hormone. Leaving out the DAC changes its pharmacokinetics compared with DAC-containing versions, which shortens its duration of action. Early research aimed at developing GHRH analogs that could modulate GH secretion for study, with CJC-1295 designed for more predictable, sustained GH-release patterns than earlier analogs.

Mechanism of Action

CJC-1295 without DAC acts as a GHRH-receptor agonist. When it binds the GHRH receptor on somatotroph cells in the anterior pituitary, it starts a signaling cascade that leads to GH synthesis and release. Native GHRH has a relatively short half-life; the modified sequence of CJC-1295 is associated with a longer duration of activity. GH is normally released in pulses, and researchers study how CJC-1295 shapes that pattern — particularly its effect on the GH/IGF-1 axis and downstream metabolism, often in combination with GHRP secretagogues.

Published Research Overview

Research on CJC-1295 covers several areas. A major focus is its effect on GH-secretion patterns and the resulting changes in circulating insulin-like growth factor 1 (IGF-1) in animal models. Studies have looked at its effects on various tissues, and at possible interactions with other GH-related peptides such as GHRPs to see whether combined effects exist. Some work has examined body composition — lean mass and fat mass — and metabolic measures such as glucose handling. Researchers have also characterized its pharmacokinetics — absorption, distribution, metabolism, and clearance — to understand how it behaves in biological systems.

Storage & Handling

CJC-1295 (99%+) is typically supplied in lyophilized (freeze-dried) form. For long-term storage, keep it at -20°C, protected from light and moisture. Before use, reconstitute with an appropriate solvent and volume set by your protocol. Avoid repeated freeze-thaw cycles, which can compromise the peptide.

Conclusion

CJC-1295 without DAC is useful for studying how growth hormone secretion is controlled and what follows downstream. Its profile suits work on the GH/IGF-1 axis, especially in combination protocols with GHRP secretagogues. Research continues to fill in its full profile. It is strictly for research use only and not intended for human or animal consumption.

Frequently Asked Questions

What is the difference between CJC-1295 with and without DAC? The Drug Affinity Complex (DAC) changes the peptide's behavior. The DAC version binds strongly to albumin, which extends its duration of action considerably. Without DAC, CJC-1295 acts for a shorter time and interacts differently, which is why it's often used in pulsatile-release research protocols.

What is the intended use of CJC-1295? Research use only. It is not intended for human or animal consumption, or for diagnostic or therapeutic use. Labs use it to study the GH/IGF-1 axis and related processes.

How should CJC-1295 be handled to maintain its integrity? Keep the lyophilized peptide frozen at -20°C, protect it from light and moisture, and reconstitute only when needed. Avoid repeated freeze-thaw cycles, and follow standard lab safety protocols including appropriate PPE.